To determine safety and tolerance of administering aerosolized recombinant interferon gamma
(IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages
by aerosolized IFN-gamma administration. To determine if subcutaneous (SC) injection of
IFN-gamma can activate alveolar macrophages in AIDS patients.
Patients must have:
- Diagnosis of AIDS with one or more opportunistic infections.
- Kaposi's sarcoma with prior history of opportunistic infection.
- Stable dose of zidovudine (AZT) therapy.
- Preserved pulmonary, renal and hepatic function.
Patients with the following conditions or symptoms are excluded:
- Presence of active infection.
- Active opportunistic infections.
- Cardiac disease.
- Central nervous system disorders.
- History of seizures.
- Irreversible airway disease.
Patients with the following are excluded:
- Co-existing conditions and symptoms listed in Patient Exclusion Co-existing
Excluded within 4 weeks of study entry:
- Immunosuppressive therapy.
- Cytotoxic therapy.
- Interferon gamma therapy.